Zejing Pharmaceutical's KRAS G12C Inhibitor Launches Clinical Trials in China

According to the China Drug Clinical Trial Registration and Information Publicity Platform, Zejing Bio has initiated a Phase 1/2 clinical study of ZG19018 in the treatment of patients with advanced solid tumors with KRAS G12C mutation

Screenshot source: Drug Clinical Trial Registration and Information Publicity Platform

KRAS is one of the most frequently mutated oncogenes in human cancers and was once a well-known "undruggable" target

According to an earlier press release from Zejing Pharma, as a selective covalent inhibitor of KRAS G12C, ZG19018 can bind to the allosteric binding pocket below the molecular switch II region of KRAS protein, and form a covalent bond with nearby Cys12 to bind KRAS G12C locks in an inactive state bound to GDP, selectively inhibits the activation of KRAS G12C, and inhibits the activation of multiple downstream signaling pathways, thereby inhibiting tumor cell proliferation and exerting an anti-tumor effect

According to Zejing Pharmaceutical, preclinical research results show that ZG19018 has a significant pharmacodynamic effect on inhibiting the growth and cell proliferation of KRAS G12C mutant tumors.

According to the China Drug Clinical Trial Registration and Information Publicity Platform, Zejing Pharma has launched a dose escalation and expansion Phase 1/2 clinical study, the main purpose is to investigate ZG19018 treatment at least after first-line standard treatment failure carrying KRAS G12C mutation Safety and tolerability in patients with advanced solid tumors or without standard therapy

It is hoped that the follow-up clinical research of Zejing Pharmaceutical's KRAS G12C inhibitor will proceed smoothly and bring more treatment options to patients with advanced tumors as soon as possible

References:

[1] China Drug Clinical Trials Registration and Information Publicity Platform.

[3] Jing Pharma Announces FDA Approval of ZG19018 Tablet Clinical Trial Application.